Cases & Deals

  • Home
  • Practices
  • Torii Pharmaceutical acquires exclusive marketing and licensing rights from BioCryst for BCX7353 in Japan

Share

Torii Pharmaceutical acquires exclusive marketing and licensing rights from BioCryst for BCX7353 in Japan

November 2019

Client(s) Torii Pharmaceutical Co., Ltd

Jones Day represented Torii Pharmaceutical Co., Ltd. in drafting, reviewing, and negotiating its commercialization and license agreement with BioCryst Pharmaceuticals, Inc. Torii has acquired exclusive licensing and marketing rights in Japan to market products containing the plasma kallikrein inhibitor BCX7353. The compound is a new oral agent that is expected to prevent hereditary angioedema ("HAE") attacks.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.